 They found both medications helped patients achieve weight loss, but Manjaro was more effective. The FDA has approved higher doses of both drugs to treat weight loss, but the new study only looked at the doses to treat type 2 diabetes. The maker of Ozempic, Novo Nordisk, criticized the study, saying it compares the diabetes version of its drug, not its weight loss version, Wegovy, despite weight loss being the main subject of that study.